Chengda Pharmaceuticals301201.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Chengda Pharmaceuticals (301201.SZ) trades at a negative P/E (-180.62x, due to a recent net loss), P/B of 1.94x, P/S of 7.94x, and a dividend yield of 0.75%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 46th percentile over the trailing 10Y window (vs. 56th percentile over 3Y); P/S sits at the 8th percentile over the trailing 10Y window (vs. 12th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 34th percentile within its industry and the 35th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.75%, ranking at the 51st percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Chengda Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 301201 · SZSE: 301201 · 301201
Want the full picture on whether Chengda Pharmaceuticals (301201.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -180.62 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.94 | ||||||
| P/S (TTM) | 7.94 | ||||||
| Dividend Yield | 0.75% | ||||||
| Buyback + Div Yield | 0.75% |